Frank Stokes's most recent trade in Castle Biosciences Inc was a trade of 6,001 Common Stock done at an average price of $28.0 . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.98 per share. | 05 Mar 2026 | 6,001 | 60,085 (0%) | 0% | 28.0 | 167,908 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2026 | 48,367 | 48,367 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 24,146 | 73,018 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 12,186 | 24,372 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 11,960 | 35,878 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.17 per share. | 03 Mar 2026 | 10,732 | 62,286 (0%) | 0% | 28.2 | 302,320 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.32 per share. | 03 Mar 2026 | 5,300 | 54,183 (0%) | 0% | 27.3 | 144,796 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 3,800 | 14,912 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 03 Mar 2026 | 3,800 | 66,086 (0%) | 0% | 3.4 | 12,844 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.57 per share. | 03 Mar 2026 | 3,611 | 48,872 (0%) | 0% | 27.6 | 99,555 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.81 per share. | 03 Mar 2026 | 1,700 | 52,483 (0%) | 0% | 27.8 | 47,277 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 8,124 | 58,450 (0%) | 0% | 0 | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 8,124 | 8,124 | - | - | Performance-Based Stock Unit | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.45 per share. | 11 Dec 2025 | 4,496 | 50,326 (0%) | 0% | 37.4 | 168,375 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 14,616 | 14,617 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 14,616 | 57,944 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.25 per share. | 09 Dec 2025 | 6,534 | 51,410 (0%) | 0% | 38.3 | 249,926 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 6,170 | 0 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 6,170 | 57,580 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.02 per share. | 09 Dec 2025 | 2,758 | 54,822 (0%) | 0% | 38.0 | 104,859 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.08 per share. | 11 Nov 2025 | 5,388 | 43,328 (0%) | 0% | 35.1 | 189,011 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2025 | 9,744 | 53,072 (0%) | 0% | 0 | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2025 | 9,744 | 0 | - | - | Performance-Based Stock Unit | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.36 per share. | 08 Aug 2025 | 4,356 | 48,716 (0%) | 0% | 19.4 | 84,332 | Common Stock |
| Exagen Inc | Frank Stokes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 9,000 | 9,000 | - | - | Stock Option(right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 47,838 | 47,838 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 12,186 | 48,776 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 12,186 | 36,558 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.23 per share. | 04 Mar 2025 | 5,448 | 43,328 (0%) | 0% | 22.2 | 121,109 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.70 per share. | 20 Feb 2025 | 8,046 | 35,319 (0%) | 0% | 26.7 | 214,828 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 14,617 | 29,233 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 14,617 | 45,440 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.91 per share. | 09 Dec 2024 | 6,571 | 38,869 (0%) | 0% | 30.9 | 203,110 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 6,169 | 6,170 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 6,169 | 46,138 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.63 per share. | 09 Dec 2024 | 2,773 | 43,365 (0%) | 0% | 29.6 | 82,164 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 2,000 | 0 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 2,000 | 40,869 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.63 per share. | 09 Dec 2024 | 900 | 39,969 (0%) | 0% | 29.6 | 26,667 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.87 per share. | 15 Nov 2024 | 6,123 | 31,623 (0%) | 0% | 29.9 | 182,894 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.40 per share. | 15 Nov 2024 | 800 | 30,823 (0%) | 0% | 30.4 | 24,323 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2024 | 9,745 | 40,568 (0%) | 0% | 0 | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2024 | 9,744 | 9,744 | - | - | Performance-Based Stock Unit | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.83 per share. | 09 Aug 2024 | 2,822 | 37,746 (0%) | 0% | 26.8 | 75,714 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.13 per share. | 07 Aug 2024 | 5,400 | 30,823 (0%) | 0% | 26.1 | 141,091 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.20 per share. | 07 Aug 2024 | 4,600 | 36,223 (0%) | 0% | 25.2 | 115,906 | Common Stock |
| Exagen Inc | Frank Stokes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 9,000 | 9,000 | - | - | Stock Option(right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 48,744 | 48,744 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 14,617 | 43,850 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 14,617 | 38,036 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 6,170 | 12,339 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Stokes Frank | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 6,170 | 39,937 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Stokes Frank | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.17 per share. | 09 Dec 2023 | 4,269 | 33,767 (0%) | 0% | 20.2 | 86,106 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 2,000 | 40,135 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.17 per share. | 09 Dec 2023 | 1,802 | 38,135 (0%) | 0% | 20.2 | 36,346 | Common Stock |
| Castle Biosciences Inc | Stokes Frank | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.17 per share. | 09 Dec 2023 | 584 | 39,551 (0%) | 0% | 20.2 | 11,779 | Common Stock |
| Exagen Inc | Frank Stokes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,000 | 9,000 | - | - | Stock Option(right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2023 | 4,000 | 18,712 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 04 Apr 2023 | 4,000 | 23,419 (0%) | 0% | 3.4 | 13,520 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 58,467 | 58,467 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 6,170 | 18,509 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 6,170 | 20,356 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2022 | 2,000 | 14,775 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.32 per share. | 09 Dec 2022 | 1,817 | 18,539 (0%) | 0% | 22.3 | 40,555 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.32 per share. | 09 Dec 2022 | 589 | 14,186 (0%) | 0% | 22.3 | 13,146 | Common Stock |
| Exagen Inc | Frank Stokes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,000 | 9,000 | - | - | Stock Option(right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 12 May 2022 | 4,000 | 12,775 (0%) | 0% | 3.4 | 13,520 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2022 | 4,000 | 22,712 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 1,114 | 8,775 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2021 | 42,550 | 42,550 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2021 | 24,679 | 24,679 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 2,000 | 8,225 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.52 per share. | 10 Dec 2021 | 895 | 7,330 (0%) | 0% | 40.5 | 36,265 | Common Stock |
| Exagen Inc | Frank Stokes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option(right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 11,600 | 28,537 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 73.02 per share. | 15 Jun 2021 | 11,600 | 5,920 (0%) | 0% | 73.0 | 847,032 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 15 Jun 2021 | 11,600 | 17,520 (0%) | 0% | 2.4 | 27,724 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 2,127 | 26,410 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 73.07 per share. | 15 Jun 2021 | 2,127 | 5,920 (0%) | 0% | 73.1 | 155,420 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 15 Jun 2021 | 2,127 | 8,047 (0%) | 0% | 2.4 | 5,084 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 15 Jun 2021 | 1,273 | 7,193 (0%) | 0% | 2.4 | 3,042 | Common Stock |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 1,273 | 25,137 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Frank Stokes | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 73.00 per share. | 15 Jun 2021 | 1,273 | 5,920 (0%) | 0% | 73 | 92,929 | Common Stock |